In recent trading, shares of Merck & Co Inc (Symbol: MRK) have crossed above the average analyst 12-month target price of $92.53, changing hands for $93.13/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental business dev...
In recent trading, shares of Merck & Co Inc (Symbol: MRK) have crossed above the average analyst 12-month target price of $92.53, changing hands for $93.13/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental business developments that may be responsible for driving the stock price higher — if things are looking up for the company, perhaps it is time for that target price to be raised. There are 15 different analyst targets within the Zacks coverage universe contributing to that average for Merck & Co Inc, but the average is just that — a mathematical average. There are analysts with lower targets than the average, including one looking for a price of $70.00. And then on the other side of the spectrum one analyst has a target as high as $110.00. The standard deviation is $10.769. But the whole reason to look at the average MRK price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with MRK crossing above that average target price of $92.53/share, investors in MRK have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $92.53 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? Below is a table showing the current thinking of the analysts that cover Merck & Co Inc: Recent MRK Analyst Ratings Breakdown » Current 1 Month Ago 2 Month Ago 3 Month Ago Strong buy ratings: 8 8 8 8 Buy ratings: 0 0 0 0 Hold ratings: 8 8 8 9 Sell ratings: 0 0 0 0 Strong sell ratings: 0 0 0 0 Average rating: 2.0 2.0 2.0 2.06 The average rating presented in the last row of the...
In recent trading, shares of Nucor Corp. (Symbol: NUE) have crossed above the average analyst 12-month target price of $158.86, changing hands for $160.77/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental business deve...
In recent trading, shares of Nucor Corp. (Symbol: NUE) have crossed above the average analyst 12-month target price of $158.86, changing hands for $160.77/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental business developments that may be responsible for driving the stock price higher — if things are looking up for the company, perhaps it is time for that target price to be raised. There are 7 different analyst targets within the Zacks coverage universe contributing to that average for Nucor Corp., but the average is just that — a mathematical average. There are analysts with lower targets than the average, including one looking for a price of $130.00. And then on the other side of the spectrum one analyst has a target as high as $188.00. The standard deviation is $20.995. But the whole reason to look at the average NUE price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with NUE crossing above that average target price of $158.86/share, investors in NUE have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $158.86 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? Below is a table showing the current thinking of the analysts that cover Nucor Corp.: Recent NUE Analyst Ratings Breakdown » Current 1 Month Ago 2 Month Ago 3 Month Ago Strong buy ratings: 2 2 2 2 Buy ratings: 0 0 0 0 Hold ratings: 5 5 5 5 Sell ratings: 0 0 0 0 Strong sell ratings: 1 1 0 0 Average rating: 2.75 2.75 2.43 2.43 The average rating presented in the last row of the a...
In recent trading, shares of Dollar Tree Inc (Symbol: DLTR) have crossed above the average analyst 12-month target price of $153.76, changing hands for $155.13/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental business...
In recent trading, shares of Dollar Tree Inc (Symbol: DLTR) have crossed above the average analyst 12-month target price of $153.76, changing hands for $155.13/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental business developments that may be responsible for driving the stock price higher — if things are looking up for the company, perhaps it is time for that target price to be raised. There are 17 different analyst targets within the Zacks coverage universe contributing to that average for Dollar Tree Inc, but the average is just that — a mathematical average. There are analysts with lower targets than the average, including one looking for a price of $115.00. And then on the other side of the spectrum one analyst has a target as high as $200.00. The standard deviation is $27.323. But the whole reason to look at the average DLTR price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with DLTR crossing above that average target price of $153.76/share, investors in DLTR have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $153.76 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? Below is a table showing the current thinking of the analysts that cover Dollar Tree Inc: Recent DLTR Analyst Ratings Breakdown » Current 1 Month Ago 2 Month Ago 3 Month Ago Strong buy ratings: 11 8 8 7 Buy ratings: 0 1 1 1 Hold ratings: 7 9 9 9 Sell ratings: 1 1 1 1 Strong sell ratings: 0 0 0 0 Average rating: 1.89 2.16 2.16 2.22 The average rating presented in th...
In recent trading, shares of Eastman Chemical Co (Symbol: EMN) have crossed above the average analyst 12-month target price of $87.41, changing hands for $89.68/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental busines...
In recent trading, shares of Eastman Chemical Co (Symbol: EMN) have crossed above the average analyst 12-month target price of $87.41, changing hands for $89.68/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental business developments that may be responsible for driving the stock price higher — if things are looking up for the company, perhaps it is time for that target price to be raised. There are 17 different analyst targets within the Zacks coverage universe contributing to that average for Eastman Chemical Co, but the average is just that — a mathematical average. There are analysts with lower targets than the average, including one looking for a price of $75.00. And then on the other side of the spectrum one analyst has a target as high as $115.00. The standard deviation is $10.265. But the whole reason to look at the average EMN price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with EMN crossing above that average target price of $87.41/share, investors in EMN have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $87.41 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? Below is a table showing the current thinking of the analysts that cover Eastman Chemical Co: Recent EMN Analyst Ratings Breakdown » Current 1 Month Ago 2 Month Ago 3 Month Ago Strong buy ratings: 6 6 6 6 Buy ratings: 0 0 0 0 Hold ratings: 10 10 10 10 Sell ratings: 0 0 0 0 Strong sell ratings: 0 0 0 0 Average rating: 2.25 2.25 2.25 2.25 The average rating presented ...
In recent trading, shares of IPG Photonics Corp (Symbol: IPGP) have crossed above the average analyst 12-month target price of $96.08, changing hands for $98.92/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental busines...
In recent trading, shares of IPG Photonics Corp (Symbol: IPGP) have crossed above the average analyst 12-month target price of $96.08, changing hands for $98.92/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental business developments that may be responsible for driving the stock price higher — if things are looking up for the company, perhaps it is time for that target price to be raised. There are 6 different analyst targets within the Zacks coverage universe contributing to that average for IPG Photonics Corp, but the average is just that — a mathematical average. There are analysts with lower targets than the average, including one looking for a price of $77.50. And then on the other side of the spectrum one analyst has a target as high as $105.00. The standard deviation is $10.365. But the whole reason to look at the average IPGP price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with IPGP crossing above that average target price of $96.08/share, investors in IPGP have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $96.08 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? Below is a table showing the current thinking of the analysts that cover IPG Photonics Corp: Recent IPGP Analyst Ratings Breakdown » Current 1 Month Ago 2 Month Ago 3 Month Ago Strong buy ratings: 6 5 5 4 Buy ratings: 0 0 0 0 Hold ratings: 4 5 5 5 Sell ratings: 1 1 1 1 Strong sell ratings: 0 0 0 1 Average rating: 2.0 2.18 2.18 2.55 The average rating presented in t...
青岛国恩科技股份有限公司（简称：“国恩科技”，股票代码：“2768”）今日在港股上市。 国恩科技发行价为36港元，发行3000万股，募资总额为10.8亿港元，扣除发行应付上市费用7960万港元，募资净额为10亿港元。 国恩科技基石投资者分别为利冠投资有限公司、SLD International Enterprises、丞安国际有限公司、申万宏源证券有限公司、First Seafront Fund ...
青岛国恩科技股份有限公司（简称：“国恩科技”，股票代码：“2768”）今日在港股上市。 国恩科技发行价为36港元，发行3000万股，募资总额为10.8亿港元，扣除发行应付上市费用7960万港元，募资净额为10亿港元。 国恩科技基石投资者分别为利冠投资有限公司、SLD International Enterprises、丞安国际有限公司、申万宏源证券有限公司、First Seafront Fund Series SPC、新嘉财富证券有限公司、Luminous Horizon、富国资产管理（香港）有限公司，一共认购4100万美元。 其中，利冠认购500万美元，SLD International Enterprises认购1026万美元，丞安国际认购230万美元，申万宏源证券认购100万美元，First Seafront Fund Series SPC认购1411万美元，新嘉财富认购192万美元，Luminous Horizon认购513万美元，富国香港认购128万美元。 国恩科技港股开盘价45港元，较发行价涨25%；收盘价为40.16港元，较发行价上涨11.56%；以收盘价计算，公司市值为121亿港元。 随着此番上市， 国恩科技形成了“A+H”股的格局。不过，截至今日收盘， 国恩科技A股股价为55.18元，较前一日下跌1%，市值为149.68亿，仍较H股溢价35%。 10个月营收174亿 国恩科技 成立于2000年12月， 是一家一家专注于化工新材料及明胶、胶原蛋白上下游产品的供应商，服务于化工行业及大健康行业，主要从事工业及商业用途产品的研发、生产及销售。 国恩科技的客户包括下游行业（如汽车、新能源及家电）的制造商及下游制造商的供应链解决方案提供商。 就公司的大健康板块而言，客户主要包括医疗及药品制造商，彼等使用公司的产品作为生产补充剂和药品等下游产品的原材料。 2016年，国恩科技收购购益青生物（专注于生产空心胶囊），标示我们进军大健康产业；2018年成立立国骐光电和广东国恩；2021年收购创业板上市公司东宝生物（股票代码：300239.SZ），深化垂直整合，并延伸大健康产业领域布局； 2022年，国恩科技完成日照国恩化学有限公司的战略投资；2024年，收购香港石化及国恩化学（东明），完成大化工产业板块纵向一体化布局。 招股书显示，国恩科技2022年、2023年、2...
Nippon Express (Taiwan) has opened the Tainan NEXT11 Warehouse in Tainan City, expanding its logistics footprint in southern Taiwan to support growing demand from semiconductor- and AI-related industries. The facility began full-scale operations in January 2026 and is situated within the Tainan Sinshih Logistics Park, developed by Uni-President Enterprises Group. NX Taiwan said the site was select...
Nippon Express (Taiwan) has opened the Tainan NEXT11 Warehouse in Tainan City, expanding its logistics footprint in southern Taiwan to support growing demand from semiconductor- and AI-related industries. The facility began full-scale operations in January 2026 and is situated within the Tainan Sinshih Logistics Park, developed by Uni-President Enterprises Group. NX Taiwan said the site was selected for its access to expressways, nearby industrial parks and its proximity to the Southern Taiwan Science Park, a major center for semiconductor manufacturing. The warehouse uses a rampway structure that allows large vehicles to access loading berths on each floor, a design intended to reduce handling time and support faster shipping. NX Taiwan said the configuration allows greater flexibility in responding to changes in customer demand. The facility is equipped with raised-floor platform loading docks, 24-hour manned security, surveillance cameras and air-conditioning systems. According to the company, these features are intended to meet the quality control and security requirements associated with semiconductor-related cargo. Masaru Kawamoto, the chairman of NX Taiwan, said at the opening ceremony, “We will be contributing to the development of Taiwan’s semiconductor industry, further enhancing the NX Group’s presence, and seeking continued growth through this Tainan NEXT11 Warehouse as we maximize our logistics capabilities to create high value for our customers.” NX Taiwan is part of Nippon Express Holdings, which operates logistics services globally. The company said the new warehouse will support storage, distribution, inspection, sorting and packaging operations, and forms part of its wider strategy to strengthen logistics capabilities in Taiwan as the market continues to expand. The company added that it plans to continue leveraging the NX Group’s global network to support customers’ international supply chains, particularly those linked to advanced manufacturing s...
Brookfield Asset Management named Connor Teskey chief executive officer, ending Bruce Flatt ’s reign atop the asset manager. “Today’s announcement is the next step in the succession process we started four years ago,” Flatt said in a statement Wednesday. “This will set up our next generation of leaders who will guide the company in the coming decades.” Flatt will continue as chair of the board, in...
Brookfield Asset Management named Connor Teskey chief executive officer, ending Bruce Flatt ’s reign atop the asset manager. “Today’s announcement is the next step in the succession process we started four years ago,” Flatt said in a statement Wednesday. “This will set up our next generation of leaders who will guide the company in the coming decades.” Flatt will continue as chair of the board, in addition to his role as CEO of the parent company Brookfield Corp . The appointment was announced in Brookfield’s fourth-quarter earnings statement. Brookfield’s distributable earnings rose by 18% to $767 million, or 47 cents per share, beating the average analyst estimate of 43 cents a share, according to data compiled by Bloomberg. The firm’s fee-bearing capital rose 12% to $603 billion during the three-month period, driven by strong fundraising of $35 billion during the quarter, bringing total capital raised to $112 billion in the past 12 months, according to the statement. “Looking ahead, we will have key flagship strategies in the market and a growing suite of complementary offerings, positioning us to drive sustained growth across multiple channels,” Teskey said in the statement. New CEO The move marks the end of an era for Flatt, who became CEO in 2002, when the firm was known as Brascan. The business was renamed to Brookfield three years later, and Flatt oversaw its transformation into a sprawling asset manager that oversees more than $1 trillion of investments through its real estate, infrastructure, renewables, private equity, insurance and credit businesses. Read More: Brookfield Readies a 36-Year-Old Striver as Next Billionaire CEO Flatt, 60, has been grooming Teskey for the role over the past few years to ensure a smooth transition. Teskey joined Brookfield in 2012 and rose to chief investment officer of the renewables arm by 2020, when Flatt appointed him to run the unit. Two years later Flatt expanded Teskey’s domain, making him president of Brookfield Asset...
Johnson Controls International press release ( JCI ): Q1 Non-GAAP EPS of $0.89 beats by $0.05 . Revenue of $5.8B (+6.8% Y/Y) beats by $160M and organic sales increased 6%. Q1 Orders +39% organically year-over-year Backlog of $18.2 billion increased 20% organically year-over-year The Company initiated fiscal 2026 second quarter continuing operations guidance: Organic sales growth of ~5% Operating l...
Johnson Controls International press release ( JCI ): Q1 Non-GAAP EPS of $0.89 beats by $0.05 . Revenue of $5.8B (+6.8% Y/Y) beats by $160M and organic sales increased 6%. Q1 Orders +39% organically year-over-year Backlog of $18.2 billion increased 20% organically year-over-year The Company initiated fiscal 2026 second quarter continuing operations guidance: Organic sales growth of ~5% Operating leverage of ~45% Adjusted EPS of ~$1.11 vs $1.05 consensus. The Company's fiscal 2026 full year continuing operations guidance is as follows: Organic sales growth of mid-single digits (unchanged) Operating leverage of ~50% (unchanged) Adjusted EPS of ~$4.70 (previously ~$4.55) (vs. $4.62 consensus). Adjusted free cash flow conversion of ~100% (unchanged) More on Johnson Controls International Johnson Controls: No Need To Panic, It's Prepared For The Next Evolution Of Cooling Johnson Controls: Upgrading To Buy On Execution And Backlog Strength Johnson Controls International Q1 2026 Earnings Preview Nvidia's CES comments reshape data-center cooling outlook, UBS says Seeking Alpha’s Quant Rating on Johnson Controls International
Wabash National press release ( WNC ): Q4 Non-GAAP EPS of -$0.93 misses by $0.17 . Revenue of $321.5M (-22.9% Y/Y) beats by $3.18M . For the first quarter, the company expects revenue be in the range of $310 million to $330 million (vs. consensus of $410.40M) and adjusted earnings per share to be in the range of ($0.95) to ($1.05) (vs. consensus of -$0.09) More on Wabash National Wabash National Q...
Wabash National press release ( WNC ): Q4 Non-GAAP EPS of -$0.93 misses by $0.17 . Revenue of $321.5M (-22.9% Y/Y) beats by $3.18M . For the first quarter, the company expects revenue be in the range of $310 million to $330 million (vs. consensus of $410.40M) and adjusted earnings per share to be in the range of ($0.95) to ($1.05) (vs. consensus of -$0.09) More on Wabash National Wabash National Q4 2025 Earnings Preview Seeking Alpha’s Quant Rating on Wabash National Historical earnings data for Wabash National Dividend scorecard for Wabash National Financial information for Wabash National
In this article NVO LLY Follow your favorite stocks CREATE FREE ACCOUNT Eli Lilly and Company’s logo is displayed during a press conference in Houston, Texas, U.S., Sept. 23, 2025. Antranik Tavitian | Reuters Eli Lilly on Wednesday posted fourth-quarter earnings and revenue and 2026 guidance that blew past estimates, as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mo...
In this article NVO LLY Follow your favorite stocks CREATE FREE ACCOUNT Eli Lilly and Company’s logo is displayed during a press conference in Houston, Texas, U.S., Sept. 23, 2025. Antranik Tavitian | Reuters Eli Lilly on Wednesday posted fourth-quarter earnings and revenue and 2026 guidance that blew past estimates, as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro soars. The pharmaceutical giant anticipates its 2026 revenue will come in between $80 billion and $83 billion. Analysts expected revenue of $77.62 billion, according to LSEG. Lilly also expected adjusted earnings to be between $33.50 and $35 per share for the year. That compares with analysts' estimate of $33.23 per share, according to LSEG. The results come after rival Novo Nordisk on Tuesday warned that it sees sales and profit declining this year , as prices fall in the U.S. and exclusivity expires for its blockbuster obesity and diabetes drugs in China, Brazil and Canada. Lilly is working to maintain its dominance in the booming market for those drugs, called GLP-1s, as Novo sees an explosive U.S. launch for its new Wegovy pill for obesity. Lilly hopes to win approval for its own oral weight loss drug, orforglipron, later this year. Here's what the company reported for the fourth quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG: Earnings per share: $7.54 adjusted vs. $6.67 expected Revenue: $19.29 billion vs. $17.96 billion expected Novo and Lilly in November announced landmark deals with President Donald Trump to slash the prices of their top-selling obesity and diabetes drugs, which are expected to eventually increase the number of prescriptions but ultimately hurt total sales. Under the agreements, Lilly and Novo agreed to slash the prices of those treatments for Medicare and Medicaid beneficiaries in 2026 and offer them directly to consumers at a discount on the Trump administration's direct-to-consumer platform, Tru...
Palantir Technologies (NASDAQ:PLTR - Get Free Report) was upgraded by analysts at Hsbc Global Res from a "hold" rating to a "strong-buy" rating in a research report issued to clients and investors on Tuesday,Zacks.com reports. Get Palantir Technologies alerts: Sign Up PLTR has been the subject of several other research reports. Mizuho set a $195.00 target price on Palantir Technologies in a resear...
Palantir Technologies (NASDAQ:PLTR - Get Free Report) was upgraded by analysts at Hsbc Global Res from a "hold" rating to a "strong-buy" rating in a research report issued to clients and investors on Tuesday,Zacks.com reports. Get Palantir Technologies alerts: Sign Up PLTR has been the subject of several other research reports. Mizuho set a $195.00 target price on Palantir Technologies in a research note on Tuesday. Truist Financial started coverage on shares of Palantir Technologies in a research report on Tuesday, January 6th. They issued a "buy" rating and a $223.00 price objective for the company. Jefferies Financial Group set a $208.00 price objective on shares of Palantir Technologies in a research note on Thursday, January 22nd. Raymond James Financial reiterated a "market perform" rating on shares of Palantir Technologies in a research note on Tuesday, November 4th. Finally, Citigroup boosted their price target on shares of Palantir Technologies from $235.00 to $260.00 and gave the company a "buy" rating in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, twelve have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $191.95. Read Our Latest Report on PLTR Palantir Technologies Trading Up 6.8% PLTR opened at $157.88 on Tuesday. Palantir Technologies has a 12 month low of $66.12 and a 12 month high of $207.52. The company has a market cap of $376.30 billion, a PE ratio of 250.61, a price-to-earnings-growth ratio of 3.72 and a beta of 1.64. The company has a 50 day moving average of $175.73 and a 200 day moving average of $173.73. Palantir Technologies (NASDAQ:PLTR - Get Free Report) last posted its earnings results on Monday, February 2nd. The company reported $0.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by ...
Uber Technologies Inc. gave a weak profit outlook and promoted an outspoken driverless-vehicle bull to be its new chief financial officer, signaling further investment in a closely watched area of the ride-hailing company’s business. The executive, Balaji Krishnamurthy , has been with Uber for more than six years and is currently vice president of strategic finance and investor relations. He will ...
Uber Technologies Inc. gave a weak profit outlook and promoted an outspoken driverless-vehicle bull to be its new chief financial officer, signaling further investment in a closely watched area of the ride-hailing company’s business. The executive, Balaji Krishnamurthy , has been with Uber for more than six years and is currently vice president of strategic finance and investor relations. He will replace current CFO Prashanth Mahendra-Rajah , who is leaving for another opportunity after less than three years at the company, according to a regulatory filing published Wednesday. The outgoing CFO will step down from his post on Feb. 16 and stay on as a senior finance adviser through July 1, the filing said. The shares fell 6% in premarket trading in New York. Uber has invested hundreds of millions of dollars in autonomous technology partners and agreed to purchase fleets of robotaxis, which it plans to eventually launch at scale on its popular ride-hailing platform. It is betting that its experience operating a profitable rideshare marketplace positions it to be a key player in a growing and increasingly crowded autonomous-vehicle ecosystem. Krishnamurthy has been known to champion Uber’s driverless strategy on social media, often defending the company’s autonomous-vehicle plans against investors who are bearish on its ability to compete with rivals such as Waymo and Tesla Inc. The management change was announced alongside Uber’s quarterly results, in which the firm provided disappointing earnings guidance for the current period even as it hinted at strong demand. Adjusted earnings per share — a metric Uber began reporting this year — is expected to be in the range of 65 cents to 72 cents in the current period, missing the average Bloomberg-compiled analyst estimate of 77 cents. The mid-point of its forecast for adjusted earnings before interest, taxes, depreciation and amortization also fell short. The weak profit forecast overshadowed rosy bookings guidance of $52 bi...
Uber press release ( UBER ): Q4 Non-GAAP EPS of $0.71 misses by $0.09 . Revenue of $14.37B (+20.2% Y/Y) beats by $50M . Trips during the quarter grew 22% year-over-year (“YoY”) to 3.8 billion, driven by Monthly Active Platform Consumers (“MAPCs") growth of 18% YoY and monthly Trips per MAPC growth of 3% YoY. Gross Bookings grew 22% YoY to $54.1 billion, and 22% on a constant currency basis. For Q1...
Uber press release ( UBER ): Q4 Non-GAAP EPS of $0.71 misses by $0.09 . Revenue of $14.37B (+20.2% Y/Y) beats by $50M . Trips during the quarter grew 22% year-over-year (“YoY”) to 3.8 billion, driven by Monthly Active Platform Consumers (“MAPCs") growth of 18% YoY and monthly Trips per MAPC growth of 3% YoY. Gross Bookings grew 22% YoY to $54.1 billion, and 22% on a constant currency basis. For Q1 2026, we anticipate: Gross Bookings of $52.0 billion to $53.5 billion, representing growth of 17% to 21% YoY on a constant currency basis. Our outlook assumes a roughly 4 percentage-point currency tailwind to total reported YoY growth. Non-GAAP EPS of $0.65 to $0.72, representing growth of 37% YoY at the midpoint. Our outlook translates to Adjusted EBITDA of $2.37 billion to $2.47 billion. More on Uber Uber Prints Cash But The Market Complains (Q4 Earnings Preview) Uber Q4 Earnings: Potential Risks And Robotaxis Stepping Stones Uber Technologies: This Ride Has Exceeded My Expectations Uber to report Q4 results amid expanding robotaxi partnerships Uber reenters Chinese market after years, starting with Macau
AMD’s data center sales boost quarter above expectations, Fed governor Miran gives up White House post, PepsiCo is accelerating affordability initiatives, and more news to start your day.
AMD’s data center sales boost quarter above expectations, Fed governor Miran gives up White House post, PepsiCo is accelerating affordability initiatives, and more news to start your day.